JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
A prominent mechanism of acquired resistance to BRAF inhibitors in BRAF (V600) -mutant melanoma is associated with the upregulation of receptor tyrosine kinases. Evidences suggested that this resistance mechanism is part of a more complex cellular adaptation process. Using an integrative strategy, we found this mechanism to invoke extensive transcriptomic, (phospho-) proteomic and phenotypic alterations that accompany a cellular transition to a de-differentiated, mesenchymal and invasive state. Even short-term BRAF-inhibitor exposure leads to an early adaptive, differentiation state change-characterized by a slow-cycling, persistent state. The early persistent state is distinct from the late proliferative, resistant state. However, both differentiation states share common signaling alterations including JUN upregulation. Motivated by the similarities, we found that co-targeting of BRAF and JUN is synergistic in killing fully resistant cells; and when used up-front, co-targeting substantially impairs the formation of the persistent subpopulation. We confirmed that JUN upregulation is a common response to BRAF inhibitor treatment in clinically treated patient tumors. Our findings demonstrate that events shared between early- and late-adaptation states provide candidate up-front co-treatment targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cell discovery - 2(2016) vom: 06., Seite 16028 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Titz, Bjoern [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF inhibition |
|---|
| Anmerkungen: |
Date Completed 20.09.2016 Date Revised 01.10.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/celldisc.2016.28 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM264501748 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM264501748 | ||
| 003 | DE-627 | ||
| 005 | 20231224210230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/celldisc.2016.28 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0881.xml |
| 035 | |a (DE-627)NLM264501748 | ||
| 035 | |a (NLM)27648299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Titz, Bjoern |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2016 | ||
| 500 | |a Date Revised 01.10.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A prominent mechanism of acquired resistance to BRAF inhibitors in BRAF (V600) -mutant melanoma is associated with the upregulation of receptor tyrosine kinases. Evidences suggested that this resistance mechanism is part of a more complex cellular adaptation process. Using an integrative strategy, we found this mechanism to invoke extensive transcriptomic, (phospho-) proteomic and phenotypic alterations that accompany a cellular transition to a de-differentiated, mesenchymal and invasive state. Even short-term BRAF-inhibitor exposure leads to an early adaptive, differentiation state change-characterized by a slow-cycling, persistent state. The early persistent state is distinct from the late proliferative, resistant state. However, both differentiation states share common signaling alterations including JUN upregulation. Motivated by the similarities, we found that co-targeting of BRAF and JUN is synergistic in killing fully resistant cells; and when used up-front, co-targeting substantially impairs the formation of the persistent subpopulation. We confirmed that JUN upregulation is a common response to BRAF inhibitor treatment in clinically treated patient tumors. Our findings demonstrate that events shared between early- and late-adaptation states provide candidate up-front co-treatment targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BRAF inhibition | |
| 650 | 4 | |a Drug resistance | |
| 650 | 4 | |a EMT | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a phospho-proteomics | |
| 700 | 1 | |a Lomova, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Hugo, Willy |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Xiangju |e verfasserin |4 aut | |
| 700 | 1 | |a Ten Hoeve, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Hubing |e verfasserin |4 aut | |
| 700 | 1 | |a Moriceau, Gatien |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Chunying |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Aayoung |e verfasserin |4 aut | |
| 700 | 1 | |a Atefi, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Komisopoulou, Evangelia |e verfasserin |4 aut | |
| 700 | 1 | |a Ribas, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Roger S |e verfasserin |4 aut | |
| 700 | 1 | |a Graeber, Thomas G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell discovery |d 2015 |g 2(2016) vom: 06., Seite 16028 |w (DE-627)NLM253920965 |x 2056-5968 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2016 |g day:06 |g pages:16028 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/celldisc.2016.28 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2016 |b 06 |h 16028 | ||